Drug Interactions between Aplitest and cladribine
This report displays the potential drug interactions for the following 2 drugs:
- Aplitest (tuberculin purified protein derivative)
- cladribine
Interactions between your drugs
tuberculin purified protein derivative cladribine
Applies to: Aplitest (tuberculin purified protein derivative) and cladribine
MONITOR: Immunosuppressed patients may have diminished response to diagnostic skin test antigens due to suppression of cell-mediated, delayed-type hypersensitivity. Falsely insignificant or false-negative results may occur in such patients, which may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents (e.g., greater than or equal to 2 mg/kg/day or 20 mg/day of prednisone or equivalent for 14 consecutive days or more), or long-term topical or inhaled corticosteroids.
MANAGEMENT: Clinicians should be aware of the potential for falsely insignificant or false-negative results when administering diagnostic skin test antigens to patients treated with immunosuppressive agents.
References
- (2001) "Product Information. Candin (candida albicans extract)." Nielsen Biosciences Inc
- (2001) "Product Information. Histolyn-Cyl (histoplasmin)." ALK Laboratories Inc
- (2001) "Product Information. Spherulin (coccidioidin skin test)." ALK Laboratories Inc
- (2001) "Product Information. MSTA Mumps Skin Test Antigen (mumps skin test antigen)." Aventis Pharmaceuticals
- (2001) "Product Information. Multitest CMI (skin test antigens, multiple)." Aventis Pharmaceuticals
- "Product Information. Tuberculin Tine Test (tuberculin purified protein derivative)." Connaught Laboratories Inc
Drug and food interactions
cladribine food
Applies to: cladribine
ADJUST DOSING INTERVAL: Oral cladribine may increase the bioavailability of other drugs, which may increase the risk or severity of adverse reactions. Cladribine tablets may contain hydroxypropyl betadex, which could form a complex with the active ingredients of other drugs, especially agents with low solubility. The clinical relevance of this interaction remains unknown.
MANAGEMENT: Administration of oral cladribine should be separated from any other oral drug by at least 3 hours.
References
- (2001) "Product Information. Leustatin (cladribine)." Ortho Biotech Inc
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- Cerner Multum, Inc. "Australian Product Information."
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.